Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck meets Street EPS estimate

MRK reported second quarter EPS of $0.77, meeting the Street consensus and down a

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE